BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 25027872)

  • 1. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
    Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
    Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
    Franco V; Chen YF; Feng JA; Li P; Wang D; Hasan E; Oparil S; Perry GJ
    Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):773-9. PubMed ID: 16922805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A.
    Zhang Q; Saito Y; Naya N; Imagawa K; Somekawa S; Kawata H; Takeda Y; Uemura S; Kishimoto I; Nakao K
    Hypertens Res; 2008 Jun; 31(6):1251-6. PubMed ID: 18716375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury.
    Ayuzawa N; Nagase M; Ueda K; Nishimoto M; Kawarazaki W; Marumo T; Aiba A; Sakurai T; Shindo T; Fujita T
    Hypertension; 2016 Jan; 67(1):99-106. PubMed ID: 26527051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo.
    Messaoudi S; Gravez B; Tarjus A; Pelloux V; Ouvrard-Pascaud A; Delcayre C; Samuel J; Launay JM; Sierra-Ramos C; Alvarez de la Rosa D; Clément K; Farman N; Jaisser F
    Hypertension; 2013 Feb; 61(2):361-7. PubMed ID: 23297371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
    Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
    Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
    Hullin R; Métrich M; Sarre A; Basquin D; Maillard M; Regamey J; Martin D
    Cardiovasc Res; 2018 Feb; 114(2):272-281. PubMed ID: 29016737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart.
    Kinoshita H; Kuwahara K; Nishida M; Jian Z; Rong X; Kiyonaka S; Kuwabara Y; Kurose H; Inoue R; Mori Y; Li Y; Nakagawa Y; Usami S; Fujiwara M; Yamada Y; Minami T; Ueshima K; Nakao K
    Circ Res; 2010 Jun; 106(12):1849-60. PubMed ID: 20448219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
    Kagiyama S; Matsumura K; Goto K; Otsubo T; Iida M
    Regul Pept; 2010 Feb; 160(1-3):133-9. PubMed ID: 19969025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
    Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
    Azibani F; Benard L; Schlossarek S; Merval R; Tournoux F; Fazal L; Polidano E; Launay JM; Carrier L; Chatziantoniou C; Samuel JL; Delcayre C
    Hypertension; 2012 Jun; 59(6):1179-87. PubMed ID: 22547442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure.
    Kuhn M; Voss M; Mitko D; Stypmann J; Schmid C; Kawaguchi N; Grabellus F; Baba HA
    Cardiovasc Res; 2004 Nov; 64(2):308-14. PubMed ID: 15485690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
    Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes.
    Tsai CF; Yang SF; Chu HJ; Ueng KC
    Int J Cardiol; 2013 Oct; 169(1):17-28. PubMed ID: 24120080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
    Kuster GM; Kotlyar E; Rude MK; Siwik DA; Liao R; Colucci WS; Sam F
    Circulation; 2005 Feb; 111(4):420-7. PubMed ID: 15687129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A.
    Holtwick R; van Eickels M; Skryabin BV; Baba HA; Bubikat A; Begrow F; Schneider MD; Garbers DL; Kuhn M
    J Clin Invest; 2003 May; 111(9):1399-407. PubMed ID: 12727932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2.
    Klaiber M; Kruse M; Völker K; Schröter J; Feil R; Freichel M; Gerling A; Feil S; Dietrich A; Londoño JE; Baba HA; Abramowitz J; Birnbaumer L; Penninger JM; Pongs O; Kuhn M
    Basic Res Cardiol; 2010 Sep; 105(5):583-95. PubMed ID: 20352235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial natriuretic peptide-mediated inhibition of microcirculatory endothelial Ca2+ and permeability response to histamine involves cGMP-dependent protein kinase I and TRPC6 channels.
    Chen W; Oberwinkler H; Werner F; Gaßner B; Nakagawa H; Feil R; Hofmann F; Schlossmann J; Dietrich A; Gudermann T; Nishida M; Del Galdo S; Wieland T; Kuhn M
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2121-9. PubMed ID: 23814119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
    Wahed MI; Watanabe K; Ma M; Yamaguchi K; Takahashi T; Tachikawa H; Kodama M; Aizawa Y
    Pharmacology; 2005 Feb; 73(2):81-8. PubMed ID: 15467302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.